1. Introduction {#s0005}
===============

In 2018, there were an estimated 320,000 invasive gastrointestinal (GI) cancers diagnosed, with \>160,000 attributable deaths [@b0005]. An estimated 300,000 patients develop brain metastases (BM) every year [@b0010]. The cancers most likely to cause BM are lung, breast, melanoma and renal cell carcinoma. GI cancers cause approximately 6% of all BM, and because of this relative "rarity", few robust reports have been published [@b0015]. A computerized search of the medical literature revealed extremely limited published data regarding the overall survival, or prognostic variables for this patient population [@b0020], [@b0025].

Patients with brain metastases are markedly heterogenous and it is well-known that outcomes vary widely by diagnosis and diagnosis-specific prognostic factors [@b0030]. Our group has published a series of articles defining and updating a prognostic index, the Graded Prognostic Assessment (GPA) for patients with various primary diagnoses (lung, breast, melanoma, renal cell and GI cancers) and BM. Our original GI-GPA was based on 209 GI cancer patients with BM diagnosed from 1985 to 2005 [@b0035], [@b0040], [@b0045], [@b0050], [@b0055]. We recently published a study of how prognostic factors have changed in this patient population in a larger contemporary cohort [@b0060]. The purpose of this study is to update the GI-GPA prognostic index with these newly identified prognostic factors.

2. Methods {#s0010}
==========

Investigators from a multi-national [@b0015] multi-institutional (18) consortium created an IRB-approved retrospective database of 845 patients with gastrointestinal cancers and newly-diagnosed BM between January 1, 2006 and December 31, 2017 using the Research Electronic Data Capture (REDCap) interactive software. After exclusions for incomplete data, 792 remained eligible for analysis. Multiple Cox regression was used to initially select and weight variables to be included in the new GI-GPA. The initial variables included in the model were KPS, age, presence of extracranial metastases, number of brain metastases, gender, stage, primary GI site, HER2 status and hemoglobin. Multiple imputation using predictive mean matching [@b0065] was used to impute missing values, so that the full sample could be used to estimate model parameters. Both effect magnitude (hazard ratio) and statistical significance were used to select variables. Weighting options were evaluated using metrics including the concordance index and R-squared, using 200 bootstrap replications to estimate out-of-sample performance. The final GPA was chosen as a balance of performance metrics and simplicity. Kaplan-Meier survival estimates were calculated for the new GPA categories. Analysis was performed using R software [@b0070], [@b0075].

3. Results {#s0015}
==========

The patient characteristics are shown in [Table 1](#t0005){ref-type="table"}. Noteworthy observations include: 1) 83% (575/693) presented with stage III or IV disease; 2) 81% (622/772) had extracranial metastases (ECM) and 42% (322/772) had liver metastases at the time of diagnosis of the BM; 3) In this cohort, the most common primary sites were: rectum (24%), esophagus (23%), right colon (13%), rectosigmoid (11%) and GE junction (9%); 4) HER2 was reported in 148/274 (54%) and was present in 59/148 (40%) of patients with gastric, esophageal and gastro-esophageal cancers. In HER2-positive patients, 63% received Trastuzumab; 5) the time from primary diagnosis to brain metastases (TPDBM) was longer in patients with lung metastases (p \< 0.01), females (p \< 0.001), colorectal cancers (p \< 0.001) and early stage (I-II) disease (p \< 0.001).Table 1Patient Characteristics, Survival and Time from Primary Diagnosis to Brain Metastases.VariableCategoryN (%)Median Survival (IQR)PTPDBM (IQR)POverall792 (100)8 (3, 18).23 (9, 51).Original GI-GPA\<0.0010.7510--1267 (34)4 (2, 12).24 (7, 48).1.5--2207 (26)7 (3, 18).24 (10, 53).2.5--3187 (24)12 (6, 21).21 (10, 45).3.5--455 (7)16 (7, 26).23 (11, 61).Not Reported76 (10)10 (4, 19).21 (9, 47).  KPS\<0.0010.866\<70113 (14)3 (1, 8).28 (7, 54).70154 (19)6 (3, 13).23 (8, 48).80207 (26)7 (3, 18).24 (10, 53).90187 (24)12 (6, 21).21 (10, 45).10055 (7)16 (7, 26).23 (11, 61).Not Reported76 (10)10 (4, 19).21 (9, 47).  Number BM\<0.0010.6101379 (48)10 (4, 22).23 (10, 47).2--3237 (30)8 (3, 17).26 (10, 56).\> 3159 (20)3 (2, 11).23 (8, 49).Not Reported17 (2)12 (8, 18).12 (0, 42).  Extracranial Mets\<0.001\<0.001Absent150 (19)14 (6, 26).13 (5, 21).Present622 (79)7 (3, 15).29 (10, 58).Not Reported20 (3)9 (3, 18).14 (8, 41).  ECM Liver\<0.0010.870Absent450 (57)10 (3, 19).22 (10, 52).Present322 (41)6 (2, 15).25 (8, 51).Not Reported20 (3)9 (3, 18).14 (8, 41).  ECM Bone\<0.0010.041Absent604 (76)9 (3, 18).22 (9, 46).Present168 (21)5 (2, 14).30 (9, 60).Not Reported20 (3)9 (3, 18).14 (8, 41).  ECM Lung0.004\<0.001Absent335 (42)9 (3, 20).13 (5, 28).Present437 (55)7 (3, 16).37 (16, 62).Not Reported20 (3)9 (3, 18).14 (8, 41).  ECM Other\<0.0010.499Absent542 (68)9 (4, 20).24 (10, 51).Present230 (29)5 (2, 14).22 (8, 52).Not Reported20 (3)9 (3, 18).14 (8, 41).  Age0.0020.15025--52195 (25)10 (4, 20).26 (12, 46).53--61186 (23)9 (3, 18).24 (9, 57).62--68214 (27)7 (3, 19).19 (7, 40).69--92197 (25)5 (2, 13).25 (9, 59).  Sex0.576\<0.001Male500 (63)8 (3, 18).20 (8, 46).Female287 (36)7 (3, 16).31 (12, 57).Not Reported5 (1)9 (8, 12).24 (8, 62).  Race0.4810.940Asian45 (6)7 (2, 14).23 (9, 55).African American37 (5)7 (3, 18).23 (16, 38).White635 (80)8 (3, 18).23 (9, 52).Unknown/Not Reported75 (9)7 (3, 18).25 (5, 44).  Ethnicity0.6110.956Not Hispanic or Latino658 (83)9 (3, 18).23 (9, 51).Hispanic or Latino62 (8)7 (3, 14).24 (9, 56).Unknown/Not Reported72 (9)5 (2, 12).26 (10, 46).  Primary Tumor Site0.009\<0.001Esophagus181 (23)10 (3, 21).12 (6, 22).GE junction73 (9)7 (2, 18).10 (4, 20).Stomach20 (3)2 (1, 6).14 (7, 23).Small Intestine (ie jejunum, d27 (3)8 (2, 14).17 (2, 53).Colon-Right100 (13)7 (3, 20).31 (12, 57).Colon-Transverse15 (2)3 (2, 5).36 (23, 57).Colon-Left35 (4)10 (4, 14).41 (22, 70).Rectosigmoid90 (11)10 (4, 20).41 (24, 67).Rectum189 (24)7 (3, 17).42 (17, 66).Anus6 (1)14 (5, 15).35 (21, 46).Gallbladder16 (2)5 (1, 17).13 (2, 27).Pancreas -- adenocarcinoma30 (4)4 (3, 14).18 (1, 45).Not Reported10 (1)15 (12, 23).66 (29, 87).  Surgical Resection of Primary Tumor0.004\<0.0010 = No276 (35)6 (2, 15).10 (1, 20).1 = Yes447 (56)9 (3, 18).40 (20, 65).Unknown69 (9)10 (4, 23).20 (3, 34).  Stage0.026\<0.0011 = I28 (4)8 (3, 17).65 (28, 102).2 = II90 (11)11 (3, 26).47 (23, 70).3 = III245 (31)9 (3, 18).34 (16, 60).4 = IV330 (42)6 (2, 16).12 (2, 28).Unknown99 (13)9 (3, 18).29 (9, 63).  [\*](#tblfn1){ref-type="table-fn"}HER20.0660.5700 = Absent89 (32)6 (2, 16).12 (7, 22).1 = Present59 (22)13 (6, 23).10 (4, 21).Not Reported126 (46)7 (2, 18).12 (5, 22).  [\*](#tblfn1){ref-type="table-fn"}KRAS0.1110.0470 = Absent111 (26)6 (3, 14).45 (23, 72).1 = Present130 (30)10 (4, 19).36 (16, 61).Not Reported188 (44)7 (3, 16).36 (15, 59).  [\*](#tblfn1){ref-type="table-fn"}KRAS Exon0.3690.7851 = G12D27 (20)8 (4, 18).29 (17, 61).2 = G12V11 (8)7 (4, 15).48 (33, 68).3 = G13D24 (18)9 (3, 20).50 (11, 77).9 = Other32 (24)14 (6, 26).36 (12, 72).Unknown39 (29)10 (3, 19).37 (15, 56).  [\*](#tblfn1){ref-type="table-fn"}BRAF0.9170.9380 = Absent130 (30)9 (4, 17).44 (21, 65).1 = Present13 (3)12 (2, 19).49 (17, 68).Not Reported286 (67)7 (3, 17).36 (16, 62).  EGFR0.1180.6080 = Absent166 (21)10 (4, 19).33 (14, 57).1 = Present16 (2)5 (2, 14).44 (13, 61).Not Reported610 (77)7 (3, 18).21 (8, 46).  PIK3CA/P13K0.3980.3770 = Absent92 (12)9 (3, 18).45 (21, 70).1 = Present15 (2)14 (6, 21).28 (16, 59).Not Reported685 (86)7 (3, 18).21 (8, 46).  [\*](#tblfn1){ref-type="table-fn"}Hx of Crohns0.3150.5130 = No353 (82)7 (3, 17).39 (19, 66).1 = Yes2 (0)6 (1, 11).28 (24, 31).Unknown74 (17)10 (4, 20).37 (19, 57).  [\*](#tblfn1){ref-type="table-fn"}Hx of Ulcerative Col0.5140.1920 = No350 (82)7 (3, 16).39 (19, 65).1 = Yes5 (1)4 (4, 20).89 (37, 91).Unknown74 (17)10 (4, 20).37 (19, 57).  Microsatellite status0.3800.8030 = Unstable8 (1)14 (6, 25).24 (16, 56).1 = Stable97 (12)8 (3, 19).30 (9, 58).Unknown687 (87)8 (3, 17).23 (9, 49).  Hemoglobin\<0.0010.473\[5, 11)121 (15)3 (1, 6).27 (9, 58).\[11, 12.5)123 (16)6 (2, 18).26 (12, 53).\[12.5, 14.1)122 (15)7 (3, 19).23 (10, 47).\[14.1, 164\]124 (16)11 (5, 19).21 (7, 51).Not Reported302 (38)12 (4, 21).21 (8, 47).  Neutrophil-to-lymphoc0.5690.498\[0.07, 3.30)76 (10)6 (3, 16).19 (11, 35).\[3.30, 6.86)80 (10)4 (3, 12).21 (5, 43).\[6.86, 12.50)76 (10)5 (2, 12).23 (10, 56).\[12.50, 112\]78 (10)4 (1, 18).22 (8, 61).Not Reported482 (61)10 (4, 19).24 (10, 52).  LDH0.1700.939\[1, 196)36 (5)7 (3, 18).22 (10, 51).\[196, 347)33 (4)4 (3, 9).25 (11, 60).\[347, 517)33 (4)7 (3, 18).17 (13, 40).\[517, 4369\]33 (4)5 (2, 14).25 (5, 60).Not Reported657 (83)9 (3, 18).24 (9, 49).  BMI0.3960.044\[11.8, 22.1)82 (10)4 (2, 17).23 (15, 54).\[22.1, 26.0)86 (11)6 (3, 16).17 (6, 38).\[26.0, 30.1)87 (11)7 (3, 22).17 (6, 44).\[30.1, 80.8\]86 (11)9 (3, 14).22 (10, 41).Not Reported451 (57)10 (3, 18).27 (10, 56).[^1]

3.1. Treatment {#s0020}
--------------

[Table 2](#t0010){ref-type="table"} shows a comparison of survival by treatment for the current cohort and our prior cohort [@b0030], [@b0035]. Notably, treatment patterns have changed from the prior cohort (1989--2007, n = 209) to the current cohort (2006--2017, n = 792). The use of whole brain radiation therapy (WBRT) alone has decreased from 45% to 21% and the use of stereotactic radiosurgery alone has increased from 17% to 39%. Detailed data on systemic therapy before and after the diagnosis of brain metastases was of interest but was not available in this retrospective study.Table 2Survival by Treatment and Treatment Era.OverallWBRTSRSWBRT+SRSS+SRSS+WBRTS+WBRT+SRSHistorical Cohort N (%)20995 (45%)35 (17%)35 (17%)2 (1%)34 (16%)8 (4%) Mean GPA2.01.82.42.13.52.41.8 Median Survival53779108 Risk of Death (HR)1.00.720.692.300.330.39 95% CI0.40, 1.280.39, 1.220.43, 12.40.19, 0.560.17, 0.90 P-value0.260.210.33\<0.010.03  Current Study N (%)792166 (21%)309 (39%)31 (4%)121 (15%)67 (8%)5 (1%) Mean GPA2.01.72.12.02.12.11.6 Median Survival8361211144 Risk of Death (HR)1.00.870.670.450.490.70 95% CI0.69, 1.100.43, 1.040.33, 0.600.35, 0.680.24, 2.07 P-value0.250.08\<0.01\<0.010.52[^2][^3]

3.2. Multivariable model {#s0025}
------------------------

The multivariable model used to select and weight factors for the GI-GPA is shown in [Table 3](#t0015){ref-type="table"}. Although 6 factors \[Karnofsky Performance Status (KPS), age, extracranial metastases (ECM), number of BM, hemoglobin and primary GI site\] were found to be significant, the predictive model was not further enhanced by adding hemoglobin or primary GI site to the index, and therefore, a simplified 4-factor model was generated.Table 3Hazard Ratio Results of Multi-Variable Analyses of Significant Prognostic Factors.ParameterCategoriesN (%)HR (95% CI)KPS90--100242 (31)1.0 (Ref)80207 (26)1.6 (1.3, 2.0)\<80267 (34)2.1 (1.6, 2.7)  Age\<60340 (43)1.0 (Ref)≥60452 (57)1.3 (1.1, 1.6)  ECMAbsent150 (19)1.0 (Ref)Present622 (79)1.8 (1.4, 2.2)  \# BM1379 (48)1.0 (Ref)2--3237 (30)1.4 (1.1, 1.7)\>3159 (20)1.9 (1.6, 2.4)[^4]

3.3. Updated GI-GPA {#s0030}
-------------------

[Table 4](#t0020){ref-type="table"} shows the definition of the updated GI-GPA and a scoring worksheet to calculate the GI-GPA for any individual patient. To compare predictive discrimination of the revised and original GI GPAs, we calculated the concordance probability (c-index) of two randomly chosen observations. If the patient predicted to live longer by the GPA actually did live longer, that pair is considered concordant. Since we have four GPA classes, about 32% of randomly chosen pairs will have the same predicted survival, thus our theoretical maximum achievable c-index is approximately 0.84. The c-index for the original GI-GPA was 0.610, which improved to 0.633 using the revised GPA.Table 4Definition of the Updated Prognostic Index, the Graded Prognostic Assessment for Patients with Gastrointestinal Cancers and Brain Metastases (GI-GPA) and Scoring Worksheet to Estimate Survival.Prognostic FactorGI-GPA Scoring CriteriaPatient Score00.51.01.52.0KPS\<80n/a80n/a90--100--Age≥60\<60n/an/an/a--ECMPresentAbsentn/an/an/a--\# of BM\>32--31n/an/a--Sum Total--[^5]

[Fig. 1](#f0005){ref-type="fig"} shows a Kaplan-Meier curve for survival by GI-GPA group showing clear separation between adjacent classes (p \< 0.001). The overall MS for this cohort was 8 months. MS by GPA group (0--1.0, 1.5--2.0, 2.5--3.0 and 3.5--4.0) was 3, 7, 11 and 17 months, respectively (p \< 0.001). MS (mo) by primary site were: anus (14 mo), left colon (10 mo), rectosigmoid (10 mo), esophagus (10 mo), small bowel (8 mo), right colon (7 mo), rectum (7 mo), GE junction (7 mo), gallbladder (5 mo), pancreas (4 mo), transverse colon (3 mo) and stomach (2 mo). [Table 3](#t0015){ref-type="table"} shows a comparison of survival by treatment and treatment era. Notably, use of WBRT decreased from 82% in the prior cohort to 34% in the contemporary era.Fig. 1Kaplan-Meier Curve for Survival by GI-GPA Group.

4. Discussion {#s0035}
=============

Brain metastases in patients with GI cancers are not uncommon. Survival varies widely within this cohort based on the prognostic factors presented in this report. In contrast to the prior cohort in which only KPS status was prognostic, this study identifies multiple new prognostic factors and incorporates them into an updated user-friendly prognostic index, the Graded Prognostic Assessment for gastrointestinal cancer patients with brain metastases (GI-GPA). Patients with GI cancers and brain metastases also represent a unique patient population because they have a worse prognosis than any other primary diagnosis except small cell lung cancer. Our findings are consistent with prior reports [@b0015], [@b0020], [@b0025], [@b0030] that performance status and number of metastases are important prognostic factors but further refine our ability to predict survival for these patients with the identification of additional factors.

Other smaller studies [@b0015], [@b0020], [@b0025] have reported that brain metastases in GI cancer patients occur late in the course of disease. Interestingly, the average time from primary diagnosis of a GI cancer to BM (TPDBM) is 23 months [@b0060] which is longer than that of lung cancer (16 mo) and renal cell carcinoma (19 mo) but shorter than the TPDBM for melanoma (32 mo) and breast cancer (38 mo). However, MS of a GI cancer patient after the diagnosis of BM (8mo) is far worse than any other diagnoses listed above. (lung non-adenocarcinoma 9 mo, lung adenocarcinoma 15 mo, breast 14 mo, melanoma 10 mo, renal cell 12 mo) [@b0030], [@b0035], [@b0040], [@b0045], [@b0050], [@b0055]. Certainly the proclivity of GI cancers to not just extracranial sites (80%) but particularly the liver (42%) is a likely explanation for the worse prognosis.

Given the fact that 83% of patients in this study presented with stage III or IV disease, physicians should be aware that such patients are at high risk for developing BM, and although a role for routine screening has not been established, any CNS symptoms deserve scrutiny.

Her2-positivity may become a prognostic factor in the future as more and more patients are being tested in the current era. In this study, HER2-positivity showed a trend (p = 0.066) toward improved survival in patients with gastric, esophageal and gastroesophageal cancers.

For patients with poor prognosis (GI-GPA ≤ 1.0), discussion of supportive care or hospice, as established by the QUARTZ trial for NSCLC BM patients [@b0080] might be reasonable. Physicians should have frank conversations with their patients and their families regarding expected survival, quality-of-life, and end-of-life care.

4.1. Limitations {#s0040}
----------------

Limitations of this study include the retrospective nature of the database and the selection bias inherent in all retrospective studies. Accordingly, one cannot conclude one treatment is better than another ([Table 2](#t0010){ref-type="table"}) based on these data. Secondly, although the sample size is large, the molecular profile was not frequently reported. Thirdly, detailed data on use of chemotherapy and immunotherapy before and after the diagnosis of brain metastases are lacking in these data. Fourthly, we grouped all primary GI sites in this analysis but each primary GI site may behave differently as suggested by the HER2 data discussed above.

5. Conclusions {#s0045}
==============

Contrary to conventional wisdom, brain metastases are not uncommon in patients with GI cancers. Furthermore, median survival within this cohort varies widely (from 3 to 17 months) based on multiple recently identified prognostic factors. Compared to other diagnoses, patients with GI cancers and BM are a unique population associated with poor prognosis overall. The updated GI-GPA prognostic index improves our ability to estimate survival for these patients and will be useful for end-of-life decision-making and stratification for future clinical trials. In order to simplify calculation of individual patient's GPA, a free, user-friendly app, which can be easily downloaded to a smart phone or clinic computer is available at [brainmetgpa.com](http://brainmetgpa.com){#ir010}.
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[^1]: Only applies to a subset of primary tumor types. PT: Primary Tumor. Median survival is in months from start of BM treatment (Kaplan-Meier estimate). IQR = Interquartile Range. TPDBM = time from primary diagnosis to start of BM treatment, in months. Variables were measured at time of BM diagnosis. P-values are from log-rank (survival) or Kruskal-Wallis (TPDBM) test of equivalence among categories, excluding unknown/not reported.

[^2]: Abbreviations: WBRT: whole brain radiation therapy; SRS: stereotactic radiosurgery; S: surgery (craniotomy).

[^3]: Hazard ratio (HR), 95% CI, and p (each treatment vs. WBRT alone within each cohort) adjusted for GPA. Median survival is unadjusted, in months. 11 patients in the current study did not have an initial treatment reported. 70 had surgery alone and 12 had fractionated partial brain radiation alone.

[^4]: Note: Two other factors (hemoglobin and primary GI site) were significant but incorporating those factors did not improve the model so were excluded for simplicity.

[^5]: Median Survival by GI-GPA Group: 0--1.0, 1.5--2.0, 2.5--3.0, 3.5--4.0 was 3, 9, 12 and 17 months, respectively. Abbreviations: KPS, Karnofsky Performance Score; ECM, extracranial metastases; \# of BM, number of brain metastases; n/a, not applicable.
